Neogenomics Inc (NASDAQ: NEO) on Friday, soared 1.78% from the previous trading day, before settling in for the closing price of $10.09. Within the past 52 weeks, NEO’s price has moved between $8.05 and $19.11.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 10.13% over the last five years. The company achieved an average annual earnings per share of 63.59%. With a float of $127.12 million, this company’s outstanding shares have now reached $128.15 million.
The firm has a total of 2200 workers. Let’s measure their productivity. In terms of profitability, gross margin is 42.87%, operating margin of -13.35%, and the pretax margin is -12.09%.
Neogenomics Inc (NEO) Insider Activity
Observing investor behavior towards Diagnostics & Research industry stocks is more important than anything else. The insider ownership of Neogenomics Inc is 1.20%, while institutional ownership is 101.29%. The most recent insider transaction that took place on Nov 15 ’24, was worth 79,475. In this transaction General Counsel of this company sold 5,175 shares at a rate of $15.36, taking the stock ownership to the 37,129 shares. Before that another transaction happened on Nov 15 ’24, when Company’s Officer proposed sale 5,175 for $15.79, making the entire transaction worth $81,713.
Neogenomics Inc (NEO) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 63.59% per share during the next fiscal year.
Neogenomics Inc (NASDAQ: NEO) Trading Performance Indicators
Neogenomics Inc (NEO) is currently performing well based on its current performance indicators. A quick ratio of 1.89 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.62, a number that is poised to hit -0.01 in the next quarter and is forecasted to reach 0.35 in one year’s time.
Technical Analysis of Neogenomics Inc (NEO)
Analysing the last 5-days average volume posted by the [Neogenomics Inc, NEO], we can find that recorded value of 1.44 million was better than the volume posted last year of 1.43 million. As of the previous 9 days, the stock’s Stochastic %D was 78.76%. Additionally, its Average True Range was 0.64.
During the past 100 days, Neogenomics Inc’s (NEO) raw stochastic average was set at 20.06%, which indicates a significant decrease from 92.89% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.57% in the past 14 days, which was lower than the 80.41% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.08, while its 200-day Moving Average is $14.15. Now, the first resistance to watch is $10.42. This is followed by the second major resistance level at $10.56. The third major resistance level sits at $10.84. If the price goes on to break the first support level at $10.00, it is likely to go to the next support level at $9.72. Should the price break the second support level, the third support level stands at $9.57.
Neogenomics Inc (NASDAQ: NEO) Key Stats
Market capitalization of the company is 1.32 billion based on 128,657K outstanding shares. Right now, sales total 660,570 K and income totals -78,730 K. The company made 172,000 K in profit during its latest quarter, and -15,320 K in sales during its previous quarter.
